健帆生物 (300529)
Jafron Biomedical Co.,Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 79860.53
- Circulating A-Shares(W): 51158.60
- Earnings Per Share(RMB): 0.5900
- Net Assets Per Share(RMB): 4.1451
- Operating Revenue(W RMB): 155602.20
- Total Profit(W RMB): 55205.39
- Net Profit Attributable to Parent(W RMB): 45323.02
- Net Profit Growth Rate(%): -42.75
- Weighted Return on Equity(%): 13.7400
- Operating Cash Flow Per Share(RMB): 0.7180
- Undistributed Profit Per Share(RMB): 2.9402
- Capital Reserve Per Share(RMB): 0.3245
2. Main Business
The main business covers:
- Research, production and sales of biomaterials and high-tech medical devices
3. Company Basic Information
- Company Name: Jafron Biomedical Co., Ltd.
- Listing Date: 2016-08-02
- Industry: Special Purpose Equipment Manufacturing
- Address: No. 98, Keji 6th Road, High-tech Zone, Zhuhai City, Guangdong Province
- Website: www.jafron.com
- Company Profile：The company's predecessor was Lizhu Group Lizhu Medical Biomaterial Factory. On April 18, 2002, the shareholders' meeting of Lizhu Biomaterial Factory resolved to restructure Lizhu Biomaterial Factory into Zhuhai Lizhu Medical Biomaterial Co., Ltd. The establishment capital contribution of Lizhu Biomaterial Co., Ltd. was verified as fully paid by Zhuhai Andeli United Accounting Firm's "Andeli Verification Report (2002) No. 338-3" issued on July 12, 2002. On August 12, 2002, Lizhu Biomaterial Co., Ltd. completed its registration with the Zhuhai Administration for Industry and Commerce, with a registered capital of RMB 2 million. The company was established by the overall change of Zhuhai Jafron Biomedical Technology Co., Ltd. On December 12, 2010, all shareholders of Jafron Biomedical Co., Ltd. unanimously agreed to change the company into Zhuhai Jafron Biomedical Technology Co., Ltd. based on the audited net asset value of RMB 121,094,580.13 as of November 30, 2010, converted into 66 million shares, with the remaining RMB 55,094,580.13 included in capital reserve. This overall change capital contribution was verified as fully paid by Lianada Certified Public Accountants Co., Ltd. Zhuhai Branch's "Lianada Verification Report [2010] No. B-1053" issued on December 15, 2010, and Ruihua Certified Public Accountants (Special General Partnership)'s Ruihua Verification Report [2014] 40030033 "Verification Review Report" issued on July 30, 2014. On December 31, 2010, the company completed the registration change procedures with the Zhuhai Administration for Industry and Commerce, with a registered capital of RMB 66 million.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Huabao China Securities Medical ETF | Fund | 1349.94 | 2.64 |
| 2 | E Fund ChiNext ETF | Fund | 920.02 | 1.80 |
| 3 | China Securities 500 ETF | Fund | 695.95 | 1.36 |
| 4 | Hong Kong Securities Clearing Company Ltd. | Northbound Funds | 621.69 | 1.22 |
| 5 | China Merchants China Securities Bio-medicine Index Fund (LOF) Class A | Fund | 614.93 | 1.20 |
| 6 | Hongtu Innovation Stable Growth Hybrid Securities Investment Fund Class A | Fund | 25.50 | 0.05 |
| 7 | Hongtu Innovation Stable Hybrid Securities Investment Fund Class A | Fund | 7.50 | 0.01 |
| 8 | Hongtu Innovation Stable Benefit 6-month Holding Period Hybrid Securities Investment Fund Class A | Fund | 5.30 | 0.01 |
| 9 | China Merchants China Securities All Share Medical Devices ETF Initiation Link Fund Class A | Fund | 0.04 | 0.00 |
5. Concept Sectors
- Convertible Bonds
- Hepatitis Concept
- Margin Trading & Securities Lending
- High-Performance Stocks
- High-Dividend Stocks
- ChiNext Index
- Technology 100
- ChiNext 300
- SZSE Innovation Index
- ChiNext Innovation
- ChiNext Blue Chips
- ChiNext Medicine
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information